Recent increase in incidence of cervical precancerous lesions in Norway: Nationwide study from 1992 to 2016

International Journal of Cancer

Volumn 145, Issue 10, 2019, Pages 2629-2638

  Orumaa, Madleen ^a   Leinonen, Maarit K ^a   Campbell, Suzanne ^a   Møller, Bjørn ^a   Myklebust, Tor Åge ^a,b   Nygård, Mari ^a  

^a CANCER REGISTRY OF NORWAY   (Norway)

^b Møre and Romsdal Hospital Trust   (Norway)

Author keywords

cervical cancer screening; cervical precancerous lesions; trend analysis

Indexed keywords

WART VIRUS VACCINE;

ADENOCARCINOMA IN SITU; ADOLESCENT; ADULT; AGE; AGED; ARTICLE; CANCER CONTROL; CANCER GRADING; CANCER INCIDENCE; CANCER REGISTRY; CANCER SCREENING; CANCER STATISTICS; CHILD; CLINICAL EFFECTIVENESS; COHORT ANALYSIS; CONTROLLED STUDY; EPIDEMIOLOGICAL DATA; FEMALE; HEALTH HAZARD; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MIDDLE AGED; NORWAY; PAPILLOMAVIRUS INFECTION; PRECANCER; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; STANDARDIZATION; THERAPEUTIC ERROR; UTERINE CERVIX ADENOCARCINOMA; UTERINE CERVIX CARCINOMA IN SITU; WART VIRUS; YOUNG ADULT;

EID: 85062589729     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.32195     Document Type: Article

References (52)

1. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136:E359–86.
2. Basu P, Ponti A, Anttila A, et al. Status of implementation and organization of cancer screening in the European Union member states-summary results from the second European screening report. Int J Cancer 2018;142:44–56.
3. IARC. European guidelines for quality assurance in cervical cancer screening, Second edn., Luxembourg: Office for Official Publications of the European Communities, 2008.
4. Landy R, Pesola F, Castanon A, et al. Impact of cervical screening on cervical cancer mortality: estimation using stage-specific results from a nested case-control study. Br J Cancer 2016;115:1140–6.
5. Cancer in Norway 2016 - Cancer incidence, mortality, survival and prevalence in Norway. The Cancer Registry of Norway, 2017.
6. Nygard JF, Skare GB, Thoresen SO. The cervical cancer screening programme in Norway, 1992-2000: changes in pap smear coverage and incidence of cervical cancer. J Med Screen 2002;9:86–91.
7. Annual report 2013–2014. Cervical Cancer screening [In Norwegian]. The Cancer Registry of Norway, 2015.
8. Annual report 2015. Cervical Cancer screening [In Norwegian]. The Cancer Registry of Norway, 2016.
9. Annual report 2016. Cervical Cancer screening [In Norwegian]. The Cancer Registry of Norway, 2018.
10. Schiffman M, Wentzensen N. Human papillomavirus infection and the multistage carcinogenesis of cervical cancer. Cancer Epidemiol Biomarkers Prev 2013;22:553–60.
11. Guan P, Howell-Jones R, Li N, et al. Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer. Int J Cancer 2012;131:2349–59.
12. Vaccarella S, Franceschi S, Engholm G, et al. 50 years of screening in the Nordic countries: quantifying the effects on cervical cancer incidence. Br J Cancer 2014;111:965–9.
13. Nygard M, Hansen BT, Dillner J, et al. Targeting human papillomavirus to reduce the burden of cervical, vulvar and vaginal cancer and pre-invasive neoplasia: establishing the baseline for surveillance. PLoS One 2014;9:e88323.
14. Hansen BT, Campbell S, Nygard M. Long-term incidence trends of HPV-related cancers, and cases preventable by HPV vaccination: a registry-based study in Norway. BMJ Open 2018;8:e019005.
15. Pedersen K, Burger EA, Nygard M, et al. Adapting cervical cancer screening for women vaccinated against human papillomavirus infections: the value of stratifying guidelines. Eur J Cancer 2018;91:68–75.
16. Quality assurance manual in Cervical Cancer Screening Programme [In Norwegian]. The Cancer Registry of Norway, 2012.
17. Larsen IK, Smastuen M, Johannesen TB, et al. Data quality at the cancer registry of Norway: an overview of comparability, completeness, validity and timeliness. Eur J Cancer 2009;45:1218–31.
18. WHO. International classification of diseases for oncology (ICD-O), 3rd edn. edition, 1st revision, Malta: World Health Organization, 2013.
19. IARC. WHO classification of Tumours of the female reproductive organs, Fourth edn. Geneva: WHO, 2014.
20. Norwegian SNOMED Coding System, available at: https://kreftregisteret.no/Registrene/Innrapportering/Rapportering-av-patologiinformasjon/. Retrieved June 6, 2018.
21. Lönnberg S, Hansen BT, Haldorsen T, et al. Cervical cancer prevented by screening: long-term incidence trends by morphology in Norway. Int J Cancer 2015;137:1758–64.
22. Doll R, Payne P, Waterhouse J. Cancer incidence in five continents: a technical report, Genève: International Union against Cancer, 1966.
23. Rutherford MJ, Lambert PC, Thompson JR. Age-period-cohort modeling. Stata J 2010;10:606–27.
24. Arbyn M, Bergeron C, Klinkhamer P, et al. Liquid compared with conventional cervical cytology: a systematic review and meta-analysis. Obstet Gynecol 2008;111:167–77.
25. Whitlock EP, Vesco KK, Eder M, et al. Liquid-based cytology and human papillomavirus testing to screen for cervical cancer: a systematic review for the U.S. preventive services task force. Ann Intern Med 2011;155:687–97. w214–5.
26. Haldorsen T, Skare GB, Ursin G, et al. Results of delayed triage by HPV testing and cytology in the Norwegian cervical cancer screening Programme. Acta Oncol 2015;54:200–9.
27. Baldur-Felskov B, Munk C, Nielsen TS, et al. Trends in the incidence of cervical cancer and severe precancerous lesions in Denmark, 1997-2012. Cancer Causes Control 2015;26:1105–16.
28. Rozemeijer K, van Kemenade FJ, Penning C, et al. Exploring the trend of increased cervical intraepithelial neoplasia detection rates in The Netherlands. J Med Screen 2015;22:144–50.
29. Stigum H, Samuelsen SO, Traeen B. Analysis of first coitus. Arch Sex Behav 2010;39:907–14.
30. Liu G, Hariri S, Bradley H, et al. Trends and patterns of sexual behaviors among adolescents and adults aged 14 to 59 years, United States. Sex Transm Dis 2015;42:20–6.
31. Guleria S, Faber MT, Hansen BT, et al. Self-perceived risk of STIs in a population-based study of Scandinavian women. Sex Transm Infect 2018;94:522–7.
32. Norwegian Institute of Public Health. Annual report. Blood brone and sexually transmitted diseases in Norway 2016 [In Norwegian]. Oslo, Norway: Norwegian Institute of Public Health, 2017.
33. Serrano B, Brotons M, Bosch FX, et al. Epidemiology and burden of HPV-related disease. Best Pract Res Clin Obstet Gynaecol 2018;47:14–26.
34. Tainio K, Athanasiou A, Tikkinen KAO, et al. Clinical course of untreated cervical intraepithelial neoplasia grade 2 under active surveillance: systematic review and meta-analysis. BMJ 2018;360:k499.
35. Schiffman M, Wentzensen N. From human papillomavirus to cervical cancer. Obstet Gynecol 2010;116:177–85.
36. IARC, IARC Handbooks of Cancer Prevention. Cervix cancer screening, vol. 10, Lyon: IARCPress, 2005.
37. Makkonen P, Heinavaara S, Sarkeala T, et al. Impact of organized and opportunistic pap testing on the risk of cervical cancer in young women - a case-control study from Finland. Gynecol Oncol 2017;147:601–6.
38. Lonnberg S, Anttila A, Luostarinen T, et al. Age-specific effectiveness of the Finnish cervical cancer screening programme. Cancer Epidemiol Biomarkers Prev 2012;21:1354–61.
39. Bruni L, Diaz M, Castellsague X, et al. Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis 2010;202:1789–99.
40. von Karsa L, Arbyn M, De Vuyst H, et al. European guidelines for quality assurance in cervical cancer screening. Summary of the supplements on HPV screening and vaccination. Papillomavirus Res 2015;1:22–31.
41. McCredie MRE, Sharples KJ, Paul C, et al. Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncol 2008;9:425–34.
42. Kyrgiou M, Athanasiou A, Kalliala IEJ, et al. Obstetric outcomes after conservative treatment for cervical intraepithelial lesions and early invasive disease. Cochrane Database Syst Rev 2017;11:Cd012847.
43. Bjørge T, Skare GB, Bjørge L, et al. Adverse pregnancy outcomes after treatment for cervical intraepithelial neoplasia. Obst Gynec 2016;128:1265–73.
44. Frederiksen ME, Vazquez-Prada Baillet M, Jensen PT, et al. Conization and healthcare use: a population-based register study. Eur J Cancer Prev 2019;28:124–130.
45. Brotherton JM, Fridman M, May CL, et al. Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study. Lancet 2011;377:2085–92.
46. Benard VB, Castle PE, Jenison SA, et al. Population-based incidence rates of cervical intraepithelial neoplasia in the human papillomavirus vaccine era. JAMA Oncol 2017;3:833–7.
47. Norwegian Institute of Public Health HPV vaccination coverage among girls born in 2004, available at: https://fhi.no/hn/helseregistre-og-registre/sysvak/dekkningsstatistikk/. Retrieved July 10, 2018.
48. Norwegian Institute of Public Health HPV vaccination coverage among women born 1991–1996, available at: http://norgeshelsa.no/norgeshelsa/. Retrieved July 10, 2018.
49. O'Brien KM, Sharp L. Trends in incidence of, and mortality from, cervical lesions in Ireland: baseline data for future evaluation of the national cervical screening programme. Cancer Epidemiol 2013;37:830–5.
50. Leinonen MK, Hansen SA, Skare GB, et al. Low proportion of unreported cervical treatments in the cancer registry of Norway between 1998 and 2013. Acta Oncol 2018;57:1663–1670.
51. Hariri S, Johnson ML, Bennett NM, et al. Population-based trends in high-grade cervical lesions in the early human papillomavirus vaccine era in the United States. Cancer 2015;121:2775–81.
52. Watson M, Soman A, Flagg EW, et al. Surveillance of high-grade cervical cancer precursors (CIN III/AIS) in four population-based cancer registries, United States, 2009-2012. Prev Med 2017;103:60–5.